EDIT at a glance
Editas Medicine, Inc. (EDIT, SEC CIK 1650664) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Editas Medicine, Inc. (EDIT) reported revenue of $40.5 million (up 25.4% from FY2024) and a net loss of $160.1 million. Diluted EPS was -$1.80.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Editas Medicine, Inc. (EDIT) shares worth $125.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Burkly Linda on September 3, 2026 of 709 shares at $3.04 per share.
- In the last 90 days, EDIT insiders reported 0 open-market purchases ($0) and 5 open-market sales ($34K) on Form 4, a net sale of $34K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $40.5M
- +25.4% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$34K
- 13F holders
- 26 funds
- $125.1M · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Net losses $43.2M for six months ended June 30, 2026 vs $129.3M in 2025
- Best-performing program EDIT-401; approximately 90%+ LDL-C reduction in preclinical NHP studies
- EDIT-401 Phase 1/2 trial targeted for 2026; topline Part 1 data expected in 2027
Risk Factors
- Patent priority risk: PTAB reaffirmed Broad’s priority on March 26, 2026; CVC appealed to the CAFC
- Regulatory risk: five parallel PTAB interferences create potential loss, narrowing, or invalidation of CRISPR/Cas9 rights
- Legal risk: ToolGen–Broad interference suspension lifted after the March 2026 remand decision
- Operational risk: adverse patent outcomes could force cessation of product-candidate development, manufacturing, or commercialization
- International IP risk: European Patent Office revoked certain in-licensed Broad patents and amended others pending appeal
AI summary of the EDIT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results covered quarter ended June 30, 2026
- Press release includes business highlights and detailed results in Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Elliott Levy resigned as class I director effective August 4, 2026, without disagreement with Editas Medicine
- Patrick Ellinor appointed independent class I director effective August 6, 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- Bernadette Connaughton and Elliott Levy elected as Class I directors through the 2029 annual meeting
- Director support varied: Connaughton 28,660,181 votes for versus 10,789,549 withheld
Item 8.01: Other Events
- Underwritten public offering priced May 26, 2026, providing financing for Editas Medicine’s operations
- Net offering proceeds plus cash at March 31, 2026 expected to fund operations into the second half of 2028
Item 1.01: Entry into a Material Definitive Agreement
- $125.0M gross equity offering: 55,555,556 shares plus warrants, priced at $2.25 per share-warrant unit
- Approximately $117.0M net proceeds, strengthening funding for Editas’ operations and clinical development
AI summaries of EDIT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for EDIT
Don't miss the next EDIT filing
- Alerts as it files. A push when EDIT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EDIT, by share count.
- Ask anything. An AI agent that reads every EDIT filing and answers with sources.
EDIT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ory Daniel Scott | A | Sep 8, 2026 | 950,000 | - |
| Burkly Linda | Sell | Sep 3, 2026 | 709 | $3.04 |
| O'Neill Gilmore Neil | Sell | Sep 3, 2026 | 5,124 | $3.04 |
| Parison Amy | Sell | Sep 3, 2026 | 453 | $3.04 |
| Ellinor Patrick Thomas II | A | Aug 6, 2026 | 103,400 | - |
| Parison Amy | Sell | Aug 3, 2026 | 678 | $2.58 |
| Burkly Linda | Sell | Jul 28, 2026 | 4,928 | $2.67 |
| Hopfield Jessica | A | Jun 17, 2026 | 51,700 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $32.3M | $40.5M |
| Operating Income | - | -$251.2M | -$160.0M |
| Net Income | -$153.2M | -$237.1M | -$160.1M |
| Op. Margin | - | -777.2% | -394.9% |
| Net Margin | - | -733.7% | -395.0% |
| Balance Sheet | |||
| Total Assets | $499.2M | $341.6M | $186.5M |
| Equity | - | $134.3M | $27.3M |
| ROE | - | -176.6% | -586.6% |
| Per Share | |||
| EPS | $-2.02 | $-2.88 | $-1.80 |
| Cash Flow | |||
| Operating CF | - | -$210.3M | -$165.2M |
| CapEx | $4.7M | $8.8M | $607K |
Source: XBRL data in Editas Medicine, Inc. (EDIT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate EDIT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $125.1M |
| Q1 2026 | 25 | $84.1M |
| Q4 2025 | 26 | $67.0M |
| Q3 2025 | 26 | $98.1M |
| Q2 2025 | 26 | $62.5M |
| Q1 2025 | 22 | $25.9M |
| Q4 2024 | 19 | $26.9M |
| Q3 2024 | 15 | $41.7M |
- Goldman Sachs Group+2.06M (+368%)
- Vanguard Capital Management LLC+1.94M (+46%)
- BlackRock+1.33M (+14%)
- Vanguard Portfolio Management LLC+449.8K (+14%)
- AQR Capital Management+201.7K (+15%)
- Renaissance Technologies LLC−1.50M (-38%)
- Citadel Advisors LLC−449.6K (-68%)
- Two Sigma Investments−216.1K (-14%)
- JPMorgan Chase & Co−84.9K (-4%)
- Morgan Stanley−69.0K (-17%)
- Millennium Management+499.0K
- StoneX Group Inc.+16.2K
- Ameriprise Financial−155.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EDIT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| SC 13G | Jun 3, 2026 | - | - | |
| SC 13G | Jun 3, 2026 | - | - | |
| SC 13G | Jun 2, 2026 | - | - | |
| 8-K | May 26, 2026 | - | Analysis | |
| 8-K | May 26, 2026 | - | Analysis | |
| 8-K | May 26, 2026 | - | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
EDIT SEC filings: frequently asked questions
Are EDIT insiders buying or selling?
In the last 90 days, Editas Medicine, Inc. (EDIT) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $33,999 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold EDIT stock?
As of June 30, 2026, the largest Editas Medicine, Inc. (EDIT) holders among the 13F filers tracked by SignalX were BlackRock ($34.3 million), Vanguard Capital Management LLC ($19.9 million), Vanguard Portfolio Management LLC ($11.7 million), Goldman Sachs Group ($8.5 million), Renaissance Technologies LLC ($8.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EDIT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Editas Medicine, Inc. (EDIT) reported revenue of $40.5 million (up 25.4% from FY2024) and a net loss of $160.1 million. Diluted EPS was -$1.80. The figures come from the XBRL data in the 10-K.
What did EDIT report in its latest 8-K?
Editas Medicine, Inc. (EDIT) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q2 2026 financial results covered quarter ended June 30, 2026.
What are the latest EDIT SEC filings?
Editas Medicine, Inc. (EDIT) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 9, 2026.
What is EDIT's SEC CIK number?
Editas Medicine, Inc. (EDIT)'s SEC Central Index Key (CIK) is 1650664. EDGAR lists every EDIT filing under that number.
Ask anything about EDIT
The research agent reads EDIT's filings, financials, insider trades and 13F holders, then answers with sources.